The Pan-American Health Organisation (PAHO) has stated that Venezuela has received its first batch of COVID-19 vaccines through the COVAX global vaccine facility intended for poor countries, Reuters news agency reported on Wednesday.
This comes after months of delays that the Venezuelan government attributed to US sanctions.
Venezuela has reportedly received 693,000 doses of Chinese biopharmaceutical company Sinovac Biotech Inc's (Nasdaq:SVA) COVID-19 vaccine, the first of a total of 11 million it will receive through COVAX, overseen by the GAVI alliance and the World Health Organisation.
So far, Venezuela has depended on Russia's Sputnik V COVID-19 vaccine and Chinese pharmaceutical company Sinopharm's shot to inoculate its population against COVID-19
An additional batch of Sputnik V COVID-19 doses has arrived this week in Venezuela, though authorities did not specify how many arrived.
According to PAHO estimates, about 3.3 million Venezuelans, or around 10% of the population, have been vaccinated.
Circio Holding and Entos Pharmaceuticals collaborate on circular RNA delivery
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100
Alzinova AB reports positive final Phase 1b results for ALZ-101 in Alzheimer's
Primrose Bio launches Prima RNApols ExTend RNA polymerase for long-template mRNA manufacturing
Merck's CAPVAXIVE approved by EC for pneumococcal disease prevention
Sanofi secures FDA fast track designation for chlamydia vaccine candidate
Anixa Biosciences secures US patent allowance for ovarian cancer vaccine
Valneva to supply IXCHIQ vaccine for chikungunya outbreak in La Réunion
Everest Medicines' EVM14 IND application receives US FDA approval
Clover Biopharmaceuticals' SCB-1019 IND application receives US FDA approval
Centivax partners with Emery Pharma on universal flu vaccine
Avance Biosciences registers with CLIA program
GSK receives approval from US FDA for Penmenvy 5-in-1 meningitis vaccine
hVIVO secures GBP2m contract for final stage of hMPV characterisation study
EU approves CSL and Arcturus Therapeutics' self-amplifying mRNA COVID-19 vaccine